10-Q: Cidara Therapeutics Reacquires CD388 Rights, Secures $240 Million in Private Placement

Cidara Therapeutics reacquired global rights to CD388, its influenza drug candidate, and secured $240 million in a private placement to fund its development.

Summary

• Cidara Therapeutics has reacquired the global development and commercial rights to CD388, an antiviral drug for influenza, from Johnson & Johnson.
• The company also completed a $240 million private placement led by RA Capital Management, with participation from Bain Capital Life Sciences, Biotech Value Fund, and Canaan Partners.
• The funds will be used to advance CD388 through a Phase 2b clinical trial, targeting universal prevention of seasonal and pandemic influenza.
• Cidara divested its rezafungin assets to Napp Pharmaceutical Group to focus on its Cloudbreak platform and CD388.
• The company expects to save approximately $128 million over the patent life of rezafungin due to the divestiture.
• The company had cash and cash equivalents of $164.4 million as of June 30, 2024.
• The company reported a net loss of $101.5 million for the six months ended June 30, 2024, which included an $85 million upfront payment to Johnson & Johnson.
• The company expects to continue to incur net losses into the foreseeable future.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the reacquisition of CD388 and the private placement are positive developments, the company's history of losses and the risks associated with drug development temper the overall outlook. The strategic shift to focus on the Cloudbreak platform is a positive long-term move, but the company faces significant challenges in the near term.

Positives

• The reacquisition of CD388 and the $240 million private placement provide significant funding for the company's lead program.
• The divestiture of rezafungin allows the company to focus on its core Cloudbreak platform and CD388.
• The company expects to save approximately $128 million over the patent life of rezafungin due to the divestiture.
• CD388 has the potential to provide universal protection against all known strains of seasonal and pandemic influenza.
• CBO421, the lead oncology DFC candidate, received IND clearance in July 2024.

Negatives

• The company has a history of net losses and negative cash flows from operating activities.
• The company expects to continue to incur net losses into the foreseeable future.
• The company's ability to execute its business plan depends on obtaining additional funding.
• The company's ability to generate revenue is dependent on the successful development and commercialization of its product candidates.
• The company is subject to various risks and uncertainties that could cause actual results to differ materially from those projected in forward-looking statements.

Risks

• The company needs substantial additional funding to advance CD388 beyond Phase 2b and to advance CBO421 and other Cloudbreak programs.
• The company depends heavily on the success of CD388, which has completed Phase 2a clinical development, and is very early in its efforts to develop other product candidates from its Cloudbreak program.
• Delays or difficulties in enrolling patients in clinical trials could delay or prevent regulatory approvals.
• Clinical trials for CD388 and CBO421 may be delayed, terminated, or fail to demonstrate safety and efficacy.
• The company faces substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than the company.
• The company has no experience manufacturing product candidates on a clinical or commercial scale and will be dependent on third parties for the manufacture of its product candidates.
• The company may not be able to obtain, or may experience delays in obtaining, required regulatory approvals.
• The price of the company's stock may be volatile, and investors could lose all or part of their investment.

Future Outlook

The company plans to initiate a Phase 2b study for CD388 in the fall of 2024 and expects topline data in the third quarter of 2025. The company expects to continue to incur net losses into the foreseeable future.

Management Comments

• We believe the reacquisition of CD388, along with the capital to advance it through Phase 2b development, is transformational for Cidara and especially for those who could benefit from a long-acting, universal preventative against all forms of influenza.
• The support from this top-tier syndicate of new and existing investors highlights our enthusiasm and potential for CD388, the most advanced member of our Cloudbreak DFC pipeline and the new focus of the company.
• We expect that the capital infusion from this financing, together with existing cash and the expected near-term cost savings associated with our recently announced divestiture of rezafungin to Mundipharma, positions us well to execute on the CD388 development program and advance the key assets in our pipeline.

Industry Context

The reacquisition of CD388 and the focus on the Cloudbreak platform reflect a strategic shift in the company's direction, moving away from commercialized products to focus on innovative drug development. The company is now positioned to compete in the market for novel immunotherapies, particularly in the areas of influenza and oncology.

Comparison to Industry Standards

• The company's decision to divest its commercialized product, rezafungin, is unusual for a company at this stage, as most companies would seek to leverage revenue from commercialized products to fund further development.
• The $240 million private placement is a significant amount of funding for a company of Cidara's size, indicating strong investor confidence in the potential of CD388.
• The company's focus on DFCs is a novel approach compared to traditional vaccines and monoclonal antibodies, which could provide a competitive advantage if successful.
• The company's lead oncology DFC candidate, CBO421, is targeting CD73, a clinically validated target in early/mid-stage clinical studies, which is a common approach in the industry.
• The company's Phase 2a results for CD388 showed a statistically significant antiviral effect, which is a positive sign for the drug's potential efficacy.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the dilution from the private placement, but may benefit from the potential success of CD388.
• Employees will be impacted by the strategic shift and focus on the Cloudbreak platform.
• Customers and patients may benefit from the development of new therapies for influenza and cancer.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company plans to initiate a Phase 2b clinical trial for CD388 in the fall of 2024.
• The company will continue preclinical development of CBO421 and other DFCs from its Cloudbreak platform.

Key Dates

Keywords

CD388, influenza, Cloudbreak platform, private placement, rezafungin, CBO421, clinical trials, biotechnology, immunotherapies, drug development